Working… Menu

Superior Vena Caval Obstruction (SVCO) - Management and Outcome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00259584
Recruitment Status : Completed
First Posted : November 29, 2005
Last Update Posted : August 13, 2010
Princess Margaret Hospital, Canada
Information provided by:
University Health Network, Toronto

Brief Summary:
All patients with symptomatic malignant SVCO deemed suitable for treatment either with radiation therapy or by stenting will be eligible. They will receive whichever treatment is deemed most clinically appropriate. Symptomatic response, time to onset of palliation, duration of symptom control and survival will be assessed.

Condition or disease Intervention/treatment Phase
Superior Vena Cava Syndrome Behavioral: Management and Outcome of SVCO Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Longitudinal Study of the Management and Outcome of Superior Vena Caval Obstruction (SVCO)
Study Start Date : October 2001
Actual Primary Completion Date : October 2008
Actual Study Completion Date : October 2008

Primary Outcome Measures :
  1. Improvement in an index symptom at 4 weeks as recorded by a daily symptom diary

Secondary Outcome Measures :
  1. Time to onset of palliation
  2. Duration of symptom control
  3. Survival
  4. Number of days spent in hospital
  5. Requirement for further treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Symptomatic clinical and radiological diagnosis of superior vena caval obstruction.
  • Underlying histological diagnosis deemed appropriate for palliative radiotherapy as treatment by investigator. Patients with chemosensitive tumours such as small cell lung cancer (both untreated and recurrent), lymphoma and testicular tumours, will be eligible if radiation is deemed to be appropriate treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00259584

Layout table for location information
Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
University Health Network, Toronto
Princess Margaret Hospital, Canada
Layout table for investigator information
Principal Investigator: Andrea Bezjak, MD Princess Margaret Hospital, Canada
Layout table for additonal information Identifier: NCT00259584    
Other Study ID Numbers: UHN REB 01-0770-C
First Posted: November 29, 2005    Key Record Dates
Last Update Posted: August 13, 2010
Last Verified: August 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Superior Vena Cava Syndrome
Vascular Diseases
Cardiovascular Diseases